Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase

Coronavirus Disease 2019 (COVID-19) is a deadly emerging infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is easily transmitted through the air and has a relatively long incubation time, COVID-19 has rapidly developed into a global pandemi...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Microorganisms (Basel) Ročník 9; číslo 5; s. 893
Hlavní autoři: Zandi, Keivan, Musall, Katie, Oo, Adrian, Cao, Dongdong, Liang, Bo, Hassandarvish, Pouya, Lan, Shuiyun, Slack, Ryan L., Kirby, Karen A., Bassit, Leda, Amblard, Franck, Kim, Baek, AbuBakar, Sazaly, Sarafianos, Stefan G., Schinazi, Raymond F.
Médium: Journal Article
Jazyk:angličtina
Vydáno: Switzerland MDPI AG 22.04.2021
MDPI
Témata:
ISSN:2076-2607, 2076-2607
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Coronavirus Disease 2019 (COVID-19) is a deadly emerging infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is easily transmitted through the air and has a relatively long incubation time, COVID-19 has rapidly developed into a global pandemic. As there are no antiviral agents for the prevention and treatment of this severe pathogen except for remdesivir, development of antiviral therapies to treat infected individuals remains highly urgent. Here, we showed that baicalein and baicalin exhibited significant antiviral activity against SARS-CoV-2, the causative agent of COVID-19 through in vitro studies. Our data through cell-based and biochemical studies showed that both compounds act as SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitors directly and inhibit the activity of the SARS-CoV-2 RdRp, but baicalein was more potent. We also showed specific binding of baicalein to the SARS-CoV-2 RdRp, making it a potential candidate for further studies towards therapeutic development for COVID-19 as a selective non-nucleoside polymerase inhibitor.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2076-2607
2076-2607
DOI:10.3390/microorganisms9050893